Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

GLEN DALE, W.Va. — Reynolds Memorial Hospital has performed its first implantation of the Altaviva device, a new treatment option designed to help manage bladder control symptoms.Hospital officials ...

Lifestyle changes like reducing caffeine and managing fluid intake are recommended before using medications for overactive ...

NEW YORK, June 6 (Reuters) - One of the most common problems in the United States -- an overactive bladder -- is so poorly treated by the current crop of drugs that new medicines have big sales ...

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...